webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Cys-mcMMAD

  CAS No.:   Cat No.: BADC-00803 4.5  

Cys-mcMMAD is a maleimide-based ADC linker with a cytotoxic monomethyl auristatin derivative, optimized for cysteine conjugation sites in antibody-drug conjugates. This molecule improves ADC stability and drug release profiles in cancer treatment. Keywords: maleimide linker, cysteine conjugation, MMA derivative, ADC payload.

Cys-mcMMAD

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C54H84N8O11S2
Molecular Weight
1085.42
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Canonical SMILES
CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)CCCCCN4C(=O)CC(C4=O)SCC(C(=O)O)N
InChI
InChI=1S/C54H84N8O11S2/c1-12-34(6)47(40(72-10)29-43(64)61-26-19-22-39(61)48(73-11)35(7)49(66)57-38(51-56-24-27-74-51)28-36-20-15-13-16-21-36)60(9)53(69)45(32(2)3)58-50(67)46(33(4)5)59(8)42(63)23-17-14-18-25-62-44(65)30-41(52(62)68)75-31-37(55)54(70)71/h13,15-16,20-21,24,27,32-35,37-41,45-48H,12,14,17-19,22-23,25-26,28-31,55H2,1-11H3,(H,57,66)(H,58,67)(H,70,71)/t34-,35+,37-,38-,39-,40+,41?,45-,46-,47-,48+/m0/s1
InChIKey
XHAWAHGMCWXSGV-HVDWHEIVSA-N
Shipping
Room temperature

Cys-mcMMAD, a potent cytotoxic payload utilized in antibody-drug conjugates (ADCs) for precision cancer therapy. Here are four key applications of Cys-mcMMAD:

Targeted Cancer Therapy: Integral to ADC development, Cys-mcMMAD is fused with antibodies that exhibit precise recognition and binding to malignant cells, facilitating targeted destruction. Upon interaction, the ADC penetrates the cancer cell, releasing the cytotoxic Cys-mcMMAD and triggering cell demise. This strategic approach minimizes harm to healthy tissues while amplifying the efficacy of cancer treatment.

Drug Development: Within the realm of preclinical investigations, researchers harness Cys-mcMMAD to assess the therapeutic potential of novel cancer-targeting antibodies. Through conjugating antibodies with Cys-mcMMAD, they scrutinize the specificity, potency, and safety of the ADCs across diverse cancer models. These studies play a pivotal role in refining ADC formulation before progression to clinical experimentation.

Mechanism of Action Studies: Cys-mcMMAD functions as a key tool in dissecting the intracellular mechanisms engaged by ADCs. By monitoring the cellular uptake, trafficking, and processing of Cys-mcMMAD, scientists unveil the intricate processes through which these conjugates enact cancer cell death. This comprehension aids in identifying determinants impacting ADC efficacy and resistance patterns.

Combination Therapy: The evaluation of Cys-mcMMAD-based ADCs, in conjunction with other therapeutic modalities, seeks to elevate overall treatment efficacy. Pairing ADCs with immune checkpoint inhibitors or traditional chemotherapeutics fosters synergistic effects, bolstering the therapeutic impact and potentially circumventing resistance mechanisms. This integrative strategy aims to offer robust and multifaceted approaches to combatting cancer.

1. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice
Wei Song, Leslie Lorello, Judy Lucas, Nicole Duriga, Quazi Shakey, Puja Sapra, Yanhua Zhang, Brian Rago, James McNally, JoAnn Wentland, Eugene Kadar, Mauricio Leal, Xiaogang Han, Franklin Spriggs Bioconjug Chem . 2015 Nov 18;26(11):2223-32. doi: 10.1021/acs.bioconjchem.5b00205.
The pharmacokinetics of an antibody (huA1)-drug (auristatin microtubule disrupting MMAF) conjugate, targeting 5T4-expressing cells, were characterized during the discovery and development phases in female nu/nu mice and cynomolgus monkeys after a single dose and in S-D rats and cynomolgus monkeys from multidose toxicity studies. Plasma/serum samples were analyzed using an ELISA-based method for antibody and conjugate (ADC) as well as for the released payload using an LC-MS/MS method. In addition, the distribution of the Ab, ADC, and released payload (cys-mcMMAF) was determined in a number of tissues (tumor, lung, liver, kidney, and heart) in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) using similar LBA and LC-MS/MS methods. Tissue distribution studies revealed preferential tumor distribution of cys-mcMMAF and its relative specificity to the 5T4 target containing tissue (tumor). Single dose studies suggests lower CL values at the higher doses in mice, although a linear relationship was seen in cynomolgus monkeys at doses from 0.3 to 10 mg/kg with no evidence of TMDD. Evaluation of DAR (drug-antibody ratio) in cynomolgus monkeys (at 3 mg/kg) indicated that at least half of the payload was still on the ADC 1 to 2 weeks after IV dosing. After multiple doses, the huA1 and conjugate data in rats and monkeys indicate that exposure (AUC) increases with increasing dose in a linear fashion. Systemic exposure (as assessed by Cmax and AUC) of the released payload increased with increasing dose, although exposure was very low and its pharmacokinetics appeared to be formation rate limited. The incidence of ADA was generally low in rats and monkeys. We will discuss cross species comparison, relationships between the Ab, ADC, and released payload exposure after multiple dosing, and insights into the distribution of this ADC with a focus on experimental design as a way to address or bypass apparent obstacles and its integration into predictive models.
2. Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Sara Gulesserian, Zhilan Zeng, Sher Karki, Karen Morrison, Lisa Do, Josh Snyder, Fernando Doñate, Sathish Kumar Ganesan, Veronica Robles, Hui Zhao, Jimmy Ou, David R Stover, Hector Aviña Mol Cancer Ther . 2017 Sep;16(9):1877-1886. doi: 10.1158/1535-7163.MCT-16-0710.
Thrombocytopenia is a common adverse event in cancer patients treated with antibody-drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1). This study aims to elucidate the mechanism of action of ADC-induced thrombocytopenia. ENPP3 expression in platelets and megakaryocytes (MK) was investigated and shown to be negative. The direct effect of AGS-16C3F on platelets was evaluated using platelet rich plasma following the expression of platelet activation markers. Effects of AGS-16C3F, T-DM1, and control ADCs on maturing megakaryocytes were evaluated in anin vitrosystem in which human hematopoietic stem cells (HSC) were differentiated into MKs. AGS-16C3F, like T-DM1, did not affect platelets directly, but inhibited MK differentiation by the activity of Cys-mcMMAF, its active metabolite. FcγRIIA did not appear to play an important role in ADC cytotoxicity to differentiating MKs. AGS-16C3F, cytotoxic to MKs, did not bind to FcγRIIA on MKs. Blocking the interaction of T-DM1 with FcγRIIA did not prevent the inhibition of MK differentiation and IgG1-mcMMAF was not as cytotoxic to MKs despite binding to FcγRIIA. Several lines of evidence suggest that internalization of AGS-16C3F into MKs is mediated by macropinocytosis. Macropinocytosis activity of differentiating HSCs correlated with cell sensitivity to AGS-16C3F. AGS-16C3F was colocalized with a macropinocytosis marker, dextran-Texas Red in differentiating MKs. Ethyl isopropyl amiloride (EIPA), a macropinocytosis inhibitor, blocked internalization of dextran-Texas Red and AGS-16C3F. These data support the notion that inhibition of MK differentiation via macropinocytosis-mediated internalization plays a role in ADC-induced thrombocytopenia.Mol Cancer Ther; 16(9); 1877-86. ©2017 AACRSee related article by Zhao et al., p. 1866.
3. Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody-drug conjugates
Sharon Boram, Christopher A Evans, Jonathan Kehler, Kristen E Pannullo, Hermes Licea-Perez, Andrew P Mayer Bioanalysis . 2021 Sep 23. doi: 10.4155/bio-2021-0171.
Aim:Investigations have shown that for the antibody-drug conjugate (ADC) belantamab mafodotin, concentrations of the cysteine-conjugated metabolite, Cys-mcMMAF, were overestimated in the presence of the ADC during sample processing when utilizing a historical SPE method.Results:A new assay was developed utilizing an acidic protein precipitation to remove the ADC early in the extraction process, thus eliminating the risk of overestimating Cys-mcMMAF in the presence of belantamab mafodotin.In vitroexperiments demonstrated a linear relationship between the concentration of belantamab mafodotin and the release of Cys-mcMMAF. Extensive stability assessments were performed to cover storage of study samples.Conclusion:This work emphasized the critical importance of understanding the performance of a bioanalytical method for free toxic payload in the presence of the ADC.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: N-Acetyl-Calicheamicin | BS3 Crosslinker disodium | Azidoethyl-SS-propionic NHS ester | BCN-PEG4-acid | MC-va-PAB-MMAD | Cys-mcMMAD
Send Inquiry
Verification code
Inquiry Basket